Germany · Delayed Price · Currency is EUR | Market Cap | 203.98M +128.9% |
| Revenue (ttm) | 67.79M +61.7% |
| Net Income | -57.57M |
| EPS | -0.57 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | n/a |
| Open | 2.740 |
| Previous Close | 2.800 |
| Day's Range | 2.740 - 2.740 |
| 52-Week Range | 0.950 - 4.580 |
| Beta | n/a |
| RSI | 39.26 |
| Earnings Date | Mar 19, 2026 |
About Cellectis
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with... [Read more]
Financial Performance
In 2025, Cellectis's revenue was $79.59 million, an increase of 61.72% compared to the previous year's $49.22 million. Losses were -$67.59 million, 83.9% more than in 2024.
Financial numbers in USD Financial StatementsNews
Cellectis SA (CLLS) Q4 2025 Earnings Call Highlights: Promising Clinical Progress and Strategic ...
Cellectis SA (CLLS) Q4 2025 Earnings Call Highlights: Promising Clinical Progress and Strategic Financial Management
Q4 2025 Cellectis SA Earnings Call Transcript
Q4 2025 Cellectis SA Earnings Call Transcript
Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update
NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to dev...
What To Expect From Cellectis SA (XPAR:ALCLS) Q4 2025 Earnings
What To Expect From Cellectis SA (XPAR:ALCLS) Q4 2025 Earnings
Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS, NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to deve...
Monthly information on share capital and company voting rights
(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of General Regulation of the French financial markets authority)
Allogene Arbitration Victory Pressures Cellectis Shares Tuesday
Shares of Cellectis S.A. (NASDAQ: CLLS) tanked on Tuesday after Allogene Therapeutics Inc. (NASDAQ: ALLO) cited a favorable arbitration outcome for partner Servier in its dispute with Cellectis relate...
Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis
Arbitration Ruling Reaffirms Allogene's Full Control of Cemacabtagene Ansegedleucel (Cema-Cel) Decision Reconfirms Allogene's Expanded Sub-License Covering EU and UK Rights with Options for Japan and ...
Cellectis Announces Arbitral Decision in Dispute with Servier
NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to deve...
ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL
NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to deve...
Cellectis Publishes Nature Communications Article on a Non-Viral Gene Editing Process Enabling Efficient Gene Insertion in Hematopoietic Stem Cells
NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to deve...
Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update
Presented data underscore the potential of lasme-cel (UCART22) and eti-cel (UCART20x22) to improve outcomes in r/r B-ALL and r/r NHL: Lasme-cel in r/r B-ALL (BALLI-01) ORR of 68% with lasme-cel Proces...
Cellectis to Present a Development Update for eti-cel at ASH 2025
NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to deve...
Cellectis to Report Third Quarter Financial Results on November 7, 2025
NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to devel...
Cellectis' R&D Day Highlights Lasme-cel's Potential to Address Significant Unmet Need for Patients with r/r B-ALL
○ Efficacy: ORR of 68% with lasme-cel Process 2 (n=22), 83% at RP2D (n=12) and 100% in the target Phase 2 population (n=9)
Top 2 Health Care Stocks That May Keep You Up At Night This Month
As of Oct. 16, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Cellectis Hosts R&D Day Today Showcasing Pipeline Progress and Long-Term Value Drivers
NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to deve...
Cellectis to Present Data on Non-Viral Gene Therapy and TALE Base Editors at the ESGCT Annual Congress
NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to deve...
Cellectis Reports Second Quarter 2025 Financial Results & Business Updates
NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to deve...
Cellectis to Report Second Quarter 2025 Financial Results on August 4, 2025
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to devel...
Cellectis Reports Results from Shareholders Meeting Held on June 26, 2025
NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving c...
Cellectis' Annual Shareholders General Meeting to be Held on June 26, 2025
NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to devel...
Cellectis Reports Financial Results for the First Quarter 2025
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to devel...
Cellectis to Report First Quarter Financial Results on May 12, 2025
NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develo...
Cellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual Meeting
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to dev...